Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases. / Anhê, Fernando F.; Jensen, Benjamin A.H.; Perazza, Lais Rossi; Tchernof, André; Schertzer, Jonathan D.; Marette, André.

In: Journal of Lipid and Atherosclerosis, Vol. 10, No. 2, 2021, p. 123-129.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Anhê, FF, Jensen, BAH, Perazza, LR, Tchernof, A, Schertzer, JD & Marette, A 2021, 'Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases', Journal of Lipid and Atherosclerosis, vol. 10, no. 2, pp. 123-129. https://doi.org/10.12997/jla.2021.10.2.123

APA

Anhê, F. F., Jensen, B. A. H., Perazza, L. R., Tchernof, A., Schertzer, J. D., & Marette, A. (2021). Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases. Journal of Lipid and Atherosclerosis, 10(2), 123-129. https://doi.org/10.12997/jla.2021.10.2.123

Vancouver

Anhê FF, Jensen BAH, Perazza LR, Tchernof A, Schertzer JD, Marette A. Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases. Journal of Lipid and Atherosclerosis. 2021;10(2):123-129. https://doi.org/10.12997/jla.2021.10.2.123

Author

Anhê, Fernando F. ; Jensen, Benjamin A.H. ; Perazza, Lais Rossi ; Tchernof, André ; Schertzer, Jonathan D. ; Marette, André. / Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases. In: Journal of Lipid and Atherosclerosis. 2021 ; Vol. 10, No. 2. pp. 123-129.

Bibtex

@article{0acf88ce71024cfdb0788bbda7106899,
title = "Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases",
abstract = "Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.",
keywords = "Akkermansia, Diabetes mellitus, type 2, Lipopolysaccharides, Obesity, Peptidoglycan",
author = "Anh{\^e}, {Fernando F.} and Jensen, {Benjamin A.H.} and Perazza, {Lais Rossi} and Andr{\'e} Tchernof and Schertzer, {Jonathan D.} and Andr{\'e} Marette",
note = "Publisher Copyright: {\textcopyright} 2021 The Korean Society of Lipid and Atherosclerosis.",
year = "2021",
doi = "10.12997/jla.2021.10.2.123",
language = "English",
volume = "10",
pages = "123--129",
journal = "Journal of Lipid and Atherosclerosis",
issn = "2287-2892",
publisher = "Korean Society of Lipid and Atherosclerosis",
number = "2",

}

RIS

TY - JOUR

T1 - Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases

AU - Anhê, Fernando F.

AU - Jensen, Benjamin A.H.

AU - Perazza, Lais Rossi

AU - Tchernof, André

AU - Schertzer, Jonathan D.

AU - Marette, André

N1 - Publisher Copyright: © 2021 The Korean Society of Lipid and Atherosclerosis.

PY - 2021

Y1 - 2021

N2 - Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.

AB - Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.

KW - Akkermansia

KW - Diabetes mellitus, type 2

KW - Lipopolysaccharides

KW - Obesity

KW - Peptidoglycan

U2 - 10.12997/jla.2021.10.2.123

DO - 10.12997/jla.2021.10.2.123

M3 - Journal article

C2 - 34095007

AN - SCOPUS:85110143772

VL - 10

SP - 123

EP - 129

JO - Journal of Lipid and Atherosclerosis

JF - Journal of Lipid and Atherosclerosis

SN - 2287-2892

IS - 2

ER -

ID: 285449134